MK-2866 and Pramipexole Interaction
MK-2866 and Pramipexole have a synergistic interaction with 55% confidence. Pramipexole supports hormonal recovery from suppression caused by MK-2866. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life. Both compounds affect the gonads, so monitoring these systems is recommended.
Compound Profiles
MK-2866
Selective Androgen Receptor Modulator | Muscle Wasting Research
MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.
View full profilePramipexole
Dopamine Agonist | Prolactin Management Alternative
Pramipexole exerts its prolactin-suppressing effects by acting as a full agonist at dopamine D2 and D3 receptors, with a marked preference for the D3 subtype. In the anterior pituitary, prolactin secretion by lactotroph cells is tonically inhibited by hypothalamic dopamine acting on D2 receptors.
View full profileCombined Organ Load
Frequently Asked Questions
Can I take MK-2866 with Pramipexole?
Yes, MK-2866 and Pramipexole can generally be taken together. Pramipexole supports hormonal recovery from suppression caused by MK-2866. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Is MK-2866 and Pramipexole safe together?
Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.
What are the interactions between MK-2866 and Pramipexole?
Pramipexole supports hormonal recovery from suppression caused by MK-2866. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life. This assessment has 55% confidence and is inferred from pharmacological mechanism analysis.
How should I time MK-2866 and Pramipexole?
MK-2866 has a half-life of ~24 hours and Pramipexole has a half-life of ~8 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.